An Overview of 1,2,3-triazole-Containing Hybrids and Their Potential Anticholinesterase Activities
Pharmaceuticals · 24.01.2023 · 16 (2) · 179
DOI: 10.3390/ph16020179 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 24.01.2023. Verfasst von Shah Alam Khan und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, National University of Science and Technology, Muscat 130, Oman. Die Arbeit wurde bisher 87-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acetylcholine (ACh) neurotransmitter of the cholinergic system in the brain is involved in learning, memory, stress responses, and cognitive functioning. It is hydrolyzed into choline and acetic acid by two key cholinesterase enzymes, viz., acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). A loss or degeneration of cholinergic neurons that leads to a reduction in ACh levels is considered a significant contributing factor in the development of neurodegenerative diseases (NDs) such as Alzheimer’s disease (AD). Numerous studies have shown that cholinesterase inhibitors can raise the level of ACh and, therefore, enhance people’s quality of life, and, at the very least, it can temporarily lessen the symptoms of NDs. 1,2,3-triazole, a five-membered heterocyclic ring, is a privileged moiety, that is, a central scaffold, and is capable of interacting with a variety of receptors and enzymes to exhibit a broad range of important biological activities. Recently, it has been clubbed with other pharmacophoric fragments/molecules in hope of obtaining potent and selective AChE and/or BuChE inhibitors. The present updated review succinctly summarizes the different synthetic strategies used to synthesize the 1,2,3-triazole moiety. It also highlights the anticholinesterase potential of various 1,2,3-triazole di/trihybrids reported in the past seven years (2015–2022), including a rationale for hybridization and with an emphasis on their structural features for the development and optimization of cholinesterase inhibitors to treat NDs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, National University of Science and Technology, Muscat 130, Oman.
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh 786004, India.
ORCID-Profile: Shah Alam Khan, Urvashee Gogoi, Dhanalekshmi Unnikrishnan Meenakshi
Zitieren
APA
Khan, S. A., Akhtar, M. J., Gogoi, U., Meenakshi, D. U., & Das, A. (2023). An Overview of 1,2,3-triazole-Containing Hybrids and Their Potential Anticholinesterase Activities. Pharmaceuticals, 16(2), 179. https://doi.org/10.3390/ph16020179
Vancouver
Khan SA, Akhtar MJ, Gogoi U, Meenakshi DU, Das A. An Overview of 1,2,3-triazole-Containing Hybrids and Their Potential Anticholinesterase Activities. Pharmaceuticals. 2023;16(2):179. doi:10.3390/ph16020179
BibTeX
@article{Khan2023,
author = {Khan, Shah Alam and Akhtar, Mohammad Jawaid and Gogoi, Urvashee and Meenakshi, Dhanalekshmi Unnikrishnan and Das, Aparoop},
title = {An Overview of 1,2,3-triazole-Containing Hybrids and Their Potential Anticholinesterase Activities},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {2},
pages = {179},
doi = {10.3390/ph16020179}
}
EUVIMED